[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide].
ACTA ACUST UNITED AC 2010;
38:660-2. [PMID:
21030284 DOI:
10.1016/j.gyobfe.2010.09.002]
[Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVES
To evaluate the effect of Temozolomide on female fertility and the relevance of our coverage in preservation of fertility.
PATIENTS AND METHODS
From 2005 to 2009, 24 patients treated with Temozolomide for a low-grade glioma were included in the study (12 women who underwent a fertility preservation consultation and 12 women who did not). A retrospective study of their medical records and sending a questionnaire were undertaken to assess their fertility after treatment.
RESULTS
Of the 24 patients, 15 patients had no fertility preservation and the remaining nine had a cryopreservation of embryos with or without an oocyte cryopreservation. Four patients are or have been pregnant (delivery, spontaneous miscarriage, pregnancy being in the group of preserving fertility and a current pregnancy in the group where no fertility preservation has been achieved).
DISCUSSION
First study on the effect of Temozolomide on female fertility.
CONCLUSION
Temozolomide is not totally gonadotoxic.
Collapse